Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par Acquisition By TPG Allows Competing Marriage Proposals

This article was originally published in The Pink Sheet Daily

Executive Summary

Par will be acquired by private equity firm TPG in $1.9 billion deal if no other suitors come forward with a better offer over the next month.

Advertisement

Related Content

Deal Watch: Endo Hopes To Boost Generics Unit With Buy-Out Of Par
Endo Continues To Expand Generics Business With Par Acquisition
Par Enters Generic Injectable Market Via JHP Buy
Deals of the Week: Aptalis For Sale
Biopharma Dealmaking Quarterly Statistics, Q3 2012
Par Pursuing Settlement Of FDA Suit And DoJ Off-Label Investigation
Deals Of The Week: Express Scripts/Walgreens, Par/TPG, Amicus/GSK
Generic Opportunities In 2012 Diluted By Shared Exclusivities
Par Gets Pumped: Teva To Divest $200 Million Of Products To Acquire Cephalon

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel